サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1703126

慢性自然じんま疹の世界市場レポート 2025年

Chronic Spontaneous Urticaria Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
慢性自然じんま疹の世界市場レポート 2025年
出版日: 2025年04月01日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

慢性自然じんま疹市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4％で30億8,000万米ドルに成長します。予測期間の成長は、CSU診断症例数の増加、患者数の開発、医療インフラ開発、患者中心のケアモデルを促進する良好な規制環境、新興市場の経済成長に起因すると考えられます。予測期間における主要動向としては、技術革新、生物学的療法の進歩、個別化医療、遠隔医療とデジタルヘルス、高度診断ツール、AIと機械学習、薬剤の承認と上市の急増などが挙げられます。

アルコール消費量の増加が予想されることから、慢性自然じんま疹市場の今後の成長が期待されます。アルコール消費の増加要因には、社会規範、ストレス、広告、手頃な価格、入手可能性などがあります。個人によっては、アルコールの摂取によって慢性自然じんま疹の症状が悪化し、じんま疹や腫れのエピソードが増加することがあります。例えば、rehabs.UKが2024年2月に報告したところによると、英国では男性の55％、女性の41％が毎週アルコールを摂取しており、男性の8％、女性の5％がほぼ毎日のアルコール摂取を報告しています。2021～2022年にかけて、アルコールのみに起因する入院患者数は34万2,795人で、人口10万人当たりの入院患者数は626人でした。したがって、アルコール消費の増加は慢性自然じんま疹市場成長の原動力となっています。

慢性自然じんま疹市場の主要企業は、治療効果の向上と投与回数の削減を目指し、次世代型ブリキリマブ（JSP191）の開発を進めています。ブリキリマブ（JSP191）は、慢性自然じんま疹のような病態を治療するために、特定の免疫細胞、特にCD47を標的にして枯渇させるように設計されたモノクローナル抗体です。例えば、2023年11月、米国を拠点とする臨床段階のバイオテクノロジー企業であるジャスパー・セラピューティクス社は、慢性自然じんま疹（CSU）を対象としたブリキリマブの第1b/2a相臨床検査において、最初の患者を投与したと発表しました。このマイルストーンは、CD47を標的とする次世代モノクローナル抗体であるBriquilimabの、じんま疹とかゆみを特徴とするこの再発性疾患に対する安全性と有効性を評価する上で重要なステップです。本検査は、ブリキリマブがCSUに罹患している患者の症状をどの程度緩和し、QOLを改善できるかを明らかにすることを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の慢性自然じんま疹PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の慢性自然じんま疹市場：成長率分析
  • 世界の慢性自然じんま疹市場の実績：規模と成長、2019～2024年
  • 世界の慢性自然じんま疹市場の予測：規模と成長、2024～2029年、2034年
  • 世界の慢性自然じんま疹総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の慢性自然じんま疹市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
  • 薬
  • 光線療法
  • その他
  • 世界の慢性自然じんま疹市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
  • 経口
  • 局所
  • 非経口
  • その他
  • 世界の慢性自然じんま疹市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
  • 身体検査
  • 血液検査
  • アレルギー検査
  • その他
  • 世界の慢性自然じんま疹市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • 専門クリニック
  • 在宅医療
  • その他
  • 世界の慢性自然じんま疹市場、医薬品のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 抗ヒスタミン薬
  • ロイコトリエン受容体拮抗薬
  • モノクローナル抗体
  • 免疫抑制剤
  • コルチコステロイド（経口と局所）
  • 世界の慢性自然じんま疹市場、光線療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • UVB光線療法
  • UVA光線療法
  • ナローバンドUVB療法
  • 世界の慢性自然じんま疹市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 代替療法
  • 食生活の変更
  • 心理療法（ストレス関連の誘因に対する）

第7章 地域別・国別分析

  • 世界の慢性自然じんま疹市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の慢性自然じんま疹市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 慢性自然じんま疹市場：競合情勢
  • 慢性自然じんま疹市場：企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co. Inc.
    • AbbVie Inc.
    • Bayer AG
    • Sanofi SA

第31章 その他の大手企業と革新的企業

  • AstraZeneca plc
  • Novartis AG
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Genentech Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals plc
  • Celltrion Inc.
  • Allakos Inc.
  • United BioPharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 慢性自然じんま疹市場、2029年：新たな機会を提供する国
  • 慢性自然じんま疹市場、2029年：新たな機会を提供するセグメント
  • 慢性自然じんま疹市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r29786

Chronic spontaneous urticaria (CSU) is a skin condition characterized by recurrent hives (raised, red, itchy welts) and angioedema (swelling) persisting for more than six weeks, without a clear external trigger. The exact cause of CSU is often unknown but may involve an autoimmune mechanism where the body's immune system erroneously targets healthy skin cells. Treatment primarily aims at managing symptoms, typically starting with antihistamines and, in more severe cases, other medications such as biologics.

The main treatments for chronic spontaneous urticaria include medication, phototherapy, and other interventions. Medication for CSU usually begins with antihistamines as the first-line approach, with options varying from non-sedating to sedating types based on the severity of symptoms and individual patient response. These medications can be administered orally, topically, parenterally, or through other routes. Diagnosis involves physical examination, blood tests, and allergy testing, and the treatments are utilized across various settings including hospitals, specialty clinics, home care settings, among others.

The chronic spontaneous urticaria research report is one of a series of new reports from The Business Research Company that provides chronic spontaneous urticaria market statistics, including the chronic spontaneous urticaria industry's global market size, regional shares, competitors with a chronic spontaneous urticaria market share, detailed chronic spontaneous urticaria market segments, market trends and opportunities, and any further data you may need to thrive in the chronic spontaneous urticaria industry. This chronic spontaneous urticaria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic spontaneous urticaria market size has grown strongly in recent years. It will grow from $2.06 billion in 2024 to $2.23 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to improved diagnostic tools, growing awareness among healthcare, patient advocacy and support groups, ongoing studies and clinical trials exploring new therapies, and growing healthcare expenditure.

The chronic spontaneous urticaria market size is expected to see strong growth in the next few years. It will grow to $3.08 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to an increase in the number of diagnosed CSU cases, a growing patient pool, healthcare infrastructure development, favorable regulatory environment facilitating, patient-centric care models, and economic growth in emerging markets. Major trends in the forecast period include technology innovations, biological therapy advancements, personalized medicine, telemedicine and digital health, advanced diagnostic tools, AI and machine learning, and surging drug approvals and launches.

The anticipated rise in alcohol consumption is expected to drive growth in the chronic spontaneous urticaria market moving forward. Factors contributing to increased alcohol consumption include social norms, stress, advertising, affordability, and availability. For some individuals, alcohol consumption can exacerbate symptoms of chronic spontaneous urticaria, leading to heightened episodes of hives and swelling. For example, rehabs.UK reported in February 2024 that 55% of men and 41% of women in the UK consume alcohol weekly, with 8% of men and 5% of women reporting near-daily alcohol consumption. Between 2021 and 2022, there were 342,795 hospital admissions attributed solely to alcohol, resulting in a rate of 626 admissions per 100,000 people. Therefore, the increasing consumption of alcohol is a driving force behind the growth of the chronic spontaneous urticaria market.

Major companies in the chronic spontaneous urticaria market are advancing the development of next-generation Briquilimab (JSP191) to improve treatment efficacy and reduce dosing frequency. Briquilimab (JSP191) is a monoclonal antibody designed to target and deplete specific immune cells, particularly by targeting CD47, to treat conditions like chronic spontaneous urticaria. For example, in November 2023, Jasper Therapeutics Inc., a U.S.-based clinical-stage biotechnology company, announced it had dosed its first patient in a Phase 1b/2a clinical trial of Briquilimab for chronic spontaneous urticaria (CSU). This milestone is a significant step in evaluating the safety and effectiveness of Briquilimab, a next-generation monoclonal antibody targeting CD47, in treating this recurrent condition characterized by hives and itching. The study aims to determine how well Briquilimab can alleviate symptoms and improve the quality of life for patients suffering from CSU.

In March 2022, Novan Inc., a specialty dermatology company in the US, acquired EPI Health LLC to strengthen its commercial infrastructure in preparation for potential FDA approval of its lead product candidate, SB206 (berdazimer gel 10.3%), for molluscum contagiosum treatment. EPI Health LLC is known for providing Xyzal (levocetirizine) for managing uncomplicated skin manifestations.

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

North America was the largest region in the chronic spontaneous urticaria market in 2024. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic spontaneous urticaria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic spontaneous urticaria market consists of revenues earned by entities by providing services such as diagnostic services and medical consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic spontaneous urticaria market also includes sales of antihistamines, corticosteroids, and cyclosporine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Spontaneous Urticaria Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic spontaneous urticaria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic spontaneous urticaria ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic spontaneous urticaria market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Medication; Phototherapy; Other Treatments
  • 2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration
  • 3) By Diagnosis: Physical Examination; Blood Test; Allergy Test; Other Diagnosis
  • 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
  • Subsegments:
  • 1) By Medication: Antihistamines; Leukotriene Receptor Antagonists; Monoclonal Antibodies; Immunosuppressants; Corticosteroids (Oral and Topical)
  • 2) By Phototherapy: UVB Phototherapy; UVA Phototherapy; Narrowband UVB Therapy
  • 3) By Other Treatments: Alternative Therapies; Dietary Modifications; Psychotherapy (for Stress-Related Triggers)
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi SA
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Spontaneous Urticaria Market Characteristics

3. Chronic Spontaneous Urticaria Market Trends And Strategies

4. Chronic Spontaneous Urticaria Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Chronic Spontaneous Urticaria Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Chronic Spontaneous Urticaria PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Chronic Spontaneous Urticaria Market Growth Rate Analysis
  • 5.4. Global Chronic Spontaneous Urticaria Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Chronic Spontaneous Urticaria Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Chronic Spontaneous Urticaria Total Addressable Market (TAM)

6. Chronic Spontaneous Urticaria Market Segmentation

  • 6.1. Global Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Medication
  • Phototherapy
  • Other Treatments
  • 6.2. Global Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Topical
  • Parenteral
  • Other Administrations
  • 6.3. Global Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Physical Examination
  • Blood Test
  • Allergy Test
  • Other Diagnosis
  • 6.4. Global Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End-Users
  • 6.5. Global Chronic Spontaneous Urticaria Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antihistamines
  • Leukotriene Receptor Antagonists
  • Monoclonal Antibodies
  • Immunosuppressants
  • Corticosteroids (Oral and Topical)
  • 6.6. Global Chronic Spontaneous Urticaria Market, Sub-Segmentation Of Phototherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • UVB Phototherapy
  • UVA Phototherapy
  • Narrowband UVB Therapy
  • 6.7. Global Chronic Spontaneous Urticaria Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alternative Therapies
  • Dietary Modifications
  • Psychotherapy (for Stress-Related Triggers)

7. Chronic Spontaneous Urticaria Market Regional And Country Analysis

  • 7.1. Global Chronic Spontaneous Urticaria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Chronic Spontaneous Urticaria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Spontaneous Urticaria Market

  • 8.1. Asia-Pacific Chronic Spontaneous Urticaria Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Spontaneous Urticaria Market

  • 9.1. China Chronic Spontaneous Urticaria Market Overview
  • 9.2. China Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Spontaneous Urticaria Market

  • 10.1. India Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Spontaneous Urticaria Market

  • 11.1. Japan Chronic Spontaneous Urticaria Market Overview
  • 11.2. Japan Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Spontaneous Urticaria Market

  • 12.1. Australia Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Spontaneous Urticaria Market

  • 13.1. Indonesia Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Spontaneous Urticaria Market

  • 14.1. South Korea Chronic Spontaneous Urticaria Market Overview
  • 14.2. South Korea Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Spontaneous Urticaria Market

  • 15.1. Western Europe Chronic Spontaneous Urticaria Market Overview
  • 15.2. Western Europe Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Spontaneous Urticaria Market

  • 16.1. UK Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Spontaneous Urticaria Market

  • 17.1. Germany Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Spontaneous Urticaria Market

  • 18.1. France Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Spontaneous Urticaria Market

  • 19.1. Italy Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Spontaneous Urticaria Market

  • 20.1. Spain Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Spontaneous Urticaria Market

  • 21.1. Eastern Europe Chronic Spontaneous Urticaria Market Overview
  • 21.2. Eastern Europe Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Spontaneous Urticaria Market

  • 22.1. Russia Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Spontaneous Urticaria Market

  • 23.1. North America Chronic Spontaneous Urticaria Market Overview
  • 23.2. North America Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Spontaneous Urticaria Market

  • 24.1. USA Chronic Spontaneous Urticaria Market Overview
  • 24.2. USA Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Spontaneous Urticaria Market

  • 25.1. Canada Chronic Spontaneous Urticaria Market Overview
  • 25.2. Canada Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Spontaneous Urticaria Market

  • 26.1. South America Chronic Spontaneous Urticaria Market Overview
  • 26.2. South America Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Spontaneous Urticaria Market

  • 27.1. Brazil Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Spontaneous Urticaria Market

  • 28.1. Middle East Chronic Spontaneous Urticaria Market Overview
  • 28.2. Middle East Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Spontaneous Urticaria Market

  • 29.1. Africa Chronic Spontaneous Urticaria Market Overview
  • 29.2. Africa Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Spontaneous Urticaria Market Competitive Landscape And Company Profiles

  • 30.1. Chronic Spontaneous Urticaria Market Competitive Landscape
  • 30.2. Chronic Spontaneous Urticaria Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Spontaneous Urticaria Market Other Major And Innovative Companies

  • 31.1. AstraZeneca plc
  • 31.2. Novartis AG
  • 31.3. GlaxoSmithKline plc
  • 31.4. Eli Lilly and Company
  • 31.5. Amgen Inc.
  • 31.6. Teva Pharmaceutical Industries Ltd.
  • 31.7. Sun Pharmaceutical Industries Ltd.
  • 31.8. Aurobindo Pharma Limited
  • 31.9. Cipla Limited
  • 31.10. Genentech Inc.
  • 31.11. Dr. Reddy's Laboratories Ltd.
  • 31.12. Hikma Pharmaceuticals plc
  • 31.13. Celltrion Inc.
  • 31.14. Allakos Inc.
  • 31.15. United BioPharma Inc.

32. Global Chronic Spontaneous Urticaria Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Spontaneous Urticaria Market

34. Recent Developments In The Chronic Spontaneous Urticaria Market

35. Chronic Spontaneous Urticaria Market High Potential Countries, Segments and Strategies

  • 35.1 Chronic Spontaneous Urticaria Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Chronic Spontaneous Urticaria Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Chronic Spontaneous Urticaria Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer